In this article, we discuss 10 small-cap growth stocks in Cathie Wood’s portfolio. If you want to skip our detailed analysis of Wood’s investment philosophy, hedge fund returns, and history, go directly to 5 Small-Cap Growth Stocks in Cathie Wood’s Portfolio.
Ark Investment Management CEO Cathie Wood has had a rough 2022 so far as her disruptive technology darlings have been among the biggest losers this year in the face of rising interest rates. Her flagship active fund Ark Innovation ETF (ARKK) is down a staggering 52% year-to-date, nearing its March 2020 low point, while her hedge fund’s assets under management in all of its ETFs declined from a peak of more than $60 billion earlier in February 2021 to $16 billion by the end of April of this year. Ironically, however, Wood’s flagship fund has posted its longest streak of inflows in over a year as it fights back from an interest rate hike-fueled decline. Investors have poured money into the $9.5 billion Ark Innovation ETF for eight straight days, with the amount totaling $639 million, according to Bloomberg.
Despite her recent woes, the innovation-focused investor remains adamant in her fund’s long-term growth. Last December, Woods predicted that Ark Investment Management would return 40% annually over the next five years, and while her losses deepened this year, she doubled down in April, saying ARK would rebound and gain 50% a year. Although she has stated that inflation has turned out to be far hotter than she had anticipated due to unprecedented supply chain disruptions and geopolitical tensions between Russian and Ukraine, Woods still has a legion of fans that are mostly sticking with her, and new money is coming in as investors seek diversification in a down market.
While some of the stocks in her portfolio have decidedly been crushed right now, including Block, Inc. (NYSE:SQ), Shopify Inc. (NYSE:SHOP), and Tesla, Inc. (NASDAQ:TSLA), Cathie Wood sought to reassure investors that she’d bounce back in 2022. In that regard, some of the top gainers could include small-cap growth stocks as well. Some of the prominent small-cap stocks in Cathie Wood’s portfolio include Pacific Biosciences of California (NASDAQ:PACB), SomaLogic, Inc. (NASDAQ:SLGC), and Schrödinger, Inc. (NASDAQ:SDGR), among others listed below.
Cathie Wood of ARK Investment Management
Our Methodology
After scouring through Cathie Wood’s 13F portfolio for the first quarter of 2022, we narrowed down a list of the top 10 small-cap growth stocks. Hedge fund data around each stock has been provided to give readers better context for their investment choices, and has been derived using Insider Monkey’s database which tracks more than 900 elite hedge funds at the end of the first quarter of 2022.
10 Small-Cap Growth Stocks in Cathie Wood’s Portfolio
10. Silvergate Capital Corporation (NYSE:SI)
Percentage of ARK Investment Management’s 13F Portfolio: 0.3%
ARK Investment Management’s Stake Value: $72.04 million
Number of Hedge Fund Holders: 35
Market Capitalization: $1.68 billion
Silvergate Capital Corporation (NYSE:SI) is a bank holding company that operates as a provider of financial infrastructure solutions and services with sizeable interests in fintech products. According to the 13F filings for the first quarter of 2022, Cathie Wood’s ARK Investment Management reported holding 478,486 shares of Silvergate Capital Corporation (NYSE:SI) worth approximately $72 million.
On June 13, Wells Fargo analyst Jared Shaw initiated coverage of Silvergate Capital Corporation (NYSE:SI) with an Overweight rating and $120 price target. According to Shaw, the firm has created a strong network effect through its Silvergate Exchange Network, which is utilized by some of the largest exchanges and institutional clients in the crypto space. He argues that the continued institutional adoption of crypto and product innovation at Silvergate should help maintain the bank’s growth profile, and believes much of the bear-case is priced in at current levels, making for an attractive entry point.
For the first quarter of 2022, Silvergate Capital Corporation (NYSE:SI) recorded an EPS of $0.80, outperforming estimates by $0.33. Quarterly revenue grew 92.7% year-on-year to come in at roughly $60 million, beating estimates by $5.1 million.
35 hedge funds were long on the company shares at the close of Q1 2022, with stakes valued at $838.6 million. This is compared to the preceding quarter where 37 hedge funds held positions in the company. Paul Marshall and Ian Wace’s Marshall Wace LLP is the company’s leading shareholder, with over 1.3 million shares.
Just like Block, Inc. (NYSE:SQ), Shopify Inc. (NYSE:SHOP), and Tesla, Inc. (NASDAQ:TSLA), Cathie Wood remains bullish on Silvergate Capital Corporation (NYSE:SI).
Investment firm Artisan Partners mentioned Silvergate Capital Corporation (NYSE:SI) in its Q3 2021 investor letter. The fund said:
“Silvergate Capital is the leading regulated provider of traditional banking solutions to the digital currency industry (DCI). Notable customers include Coinbase, Paxos, Circle, Binance, Gemini, Jane Street, Fidelity, ICE, PayPal and the CME Group. We believe the company is well positioned to grow as digital assets become an increasing part of the economy. As a bridge between regulated financial markets and the crypto industry, Silvergate has established itself as a core infrastructure layer for trading digital assets. The company provides regulated banking services to the DCI to capture low-cost funding deposits, which can be monetized through its securities and loan portfolio. As of Q3, the company had $11 billion of deposits from over 1,300 digital currency customers and processed $600 million in transaction volumes over the last 12 months through the Silvergate Exchange Network (SEN). Today, the majority of SEN transactions are not being monetized to reduce friction of growing the network; however, we believe this could become an additional profit cycle driver over time as new products are launched or if the technology is adopted for use cases such as cross-border remittance or commerce.”
9. Codexis, Inc. (NASDAQ:CDXS)
Percentage of ARK Investment Management’s 13F Portfolio: 0.33%
ARK Investment Management’s Stake Value: $81.29 million
Number of Hedge Fund Holders: 23
Market Capitalization: $710.51 million
Codexis, Inc. (NASDAQ:CDXS) is a protein engineering company that leverages its proprietary CodeEvolver platform to discover and develop high performance enzymes and novel biotherapeutics for pharmaceutical, food and medical applications. Cathie Wood’s ARK Investment Management increased its position in Codexis, Inc. (NASDAQ:CDXS) by 22% in the first quarter of 2022, holding 3.94 million shares worth $81.29 million.
Earlier this April, Codexis, Inc. (NASDAQ:CDXS) announced that its partner, Molecular Assemblies, will initiate a soft launch of its DNA synthesis platform, which uses a template-independent DNA polymerase developed under their collaboration. Sandler analyst Do Kim expects Molecular Assemblies to fully build out its commercial infrastructure in preparation for a broad 2023 launch, and enzyme supply for the company to meaningfully contribute to revenues starting in 2023, with incremental sales in 2022 from the early access program. The analyst maintained an Overweight rating and a price target of $35 on Codexis, Inc. (NASDAQ:CDXS) shares.
Among the hedge funds tracked by Insider Monkey, 23 funds were bullish on Codexis, Inc. (NASDAQ:CDXS) at the end of March 2022, up from 20 funds in the last quarter. Nantahala Capital Management is a prominent position holder in the company, with 3.3 million shares worth about $70 million.
Here is what Roubaix Capital has to say about Codexis, Inc. (NASDAQ:CDXS) in its Q4 2020 investor letter:
“The largest contributor to fourth quarter long performance was Codexis (CDXS), a truly unique investment story. The company engineers enzymes that enhance productivity of the manufacturing processes of major industries including pharmaceutical, food and other companies. The high-performance enzymes identified by Codexis enable higher levels of production, which in turn drives profits for customers. The story does not stop here. Codexis’ proprietary platform, Code Evolver, has also demonstrated early success in identifying proteins to develop novel protein and gene therapies. This adds another layer of upside optionality to the company and has validation from partnerships with Nestle and Takeda. In these instances, the company earns milestone driven incentives and royalty payments. We see Codexis’ API business generating increasing scale at the same time the pipeline around licenses and royalties has never been larger, and as a result we maintain our position.”
8. SomaLogic, Inc. (NASDAQ:SLGC)
Percentage of ARK Investment Management’s 13F Portfolio: 0.34%
ARK Investment Management’s Stake Value: $83.3 million
Number of Hedge Fund Holders: 37
Market Capitalization: $816.66 million
SomaLogic, Inc. (NASDAQ:SLGC) is a protein biomarker discovery and clinical diagnostics company located in Boulder, Colorado. The company monitors health diseases through the analysis of protein concentration changes in biological samples. Latest 13F filings show that ARK owned more than 10.39 million shares of SomaLogic, Inc. (NASDAQ:SLGC) at the end of March 2022, worth $83.3 million.
SomaLogic, Inc. (NASDAQ:SLGC) announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy on June 13. As part of the agreement, OncoHost will license SomaLogic’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, designed to predict patient response to immunotherapy treatments and provide strategies to overcome treatment resistance.
On June 23, Cowen analyst Dan Brennan lowered his price target on SomaLogic, Inc. (NASDAQ:SLGC) to $11 from $14 and maintained an Outperform rating on the shares. The analyst said the company is uniquely positioned to overcome bottlenecks created by existing tools to analyze the proteome, and believes that its durability of growth given the large market and nascent penetration is underappreciated.
At the end of the first quarter of 2022, 37 hedge funds in the database of Insider Monkey held stakes worth $434.5 million in SomaLogic, Inc. (NASDAQ:SLGC), the same as in the previous quarter worth $630 million. Eli Casdin’s Casdin Capital is the company’s biggest shareholder, with over 12.38 million shares valued at $99.36 million.
7. Schrödinger, Inc. (NASDAQ:SDGR)
Percentage of ARK Investment Management’s 13F Portfolio: 0.4%
ARK Investment Management’s Stake Value: $96.65 million
Number of Hedge Fund Holders: 22
Market Capitalization: $1.97 billion
Schrödinger, Inc. (NASDAQ:SDGR) is a New York-based life sciences and materials science company founded in 1990 that is involved in the development of software for computational chemistry and has pipeline drug discovery programs. ARK Investment Management holds 2.83 million shares of Schrödinger, Inc. (NASDAQ:SDGR), amounting to $96.65 million in worth and accounting for 0.4% of the firm’s portfolio.
On June 28, Piper Sandler analyst Do Kim said he believes Schrödinger, Inc. (NASDAQ:SDGR)’s MALT1 represents an attractive target and that the company has a “potentially best-in-class” MALT1 inhibitor. The analyst, who expects Schrödinger to out-license SGR-1505 after positive Phase 1 data in 2023, has an Overweight rating and $84 price target on the company’s shares.
By the end of the first quarter of 2022, 22 hedge funds in the database of Insider Monkey held stakes worth over $520.6 million in Schrödinger, Inc. (NASDAQ:SDGR), compared to 24 in the previous quarter worth $463.49 million. The Bill & Melinda Gates Foundation Trust held stakes in Schrödinger, Inc. (NASDAQ:SDGR) worth approximately $238.2 million, making it the company’s biggest shareholder.
Here is what Baron Growth Fund has to say about Schrödinger, Inc. (NASDAQ:SDGR) in its Q4 2021 investor letter:
“Our Disruptive Growth investments are pursuing idiosyncratic opportunities across the entirety of the global economy. Schrodinger, Inc. is pushing the boundaries of drug development by pursuing novel diagnostics and therapeutics in areas including neurodegenerative disease and blood cancers.”
6. Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Percentage of ARK Investment Management’s 13F Portfolio: 0.44%
ARK Investment Management’s Stake Value: $107 million
Number of Hedge Fund Holders: 28
Market Capitalization: $1.20 billion
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a leader in immune-driven medicine that focuses on translating the genetic language of the adaptive immune system into clinical immune-driven products to diagnose and treat diseases. As of Q1 2022, Cathie Wood’s ARK Investment Management holds over 7.7 million shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), amounting to more than $107 million in worth and representing 0.44% of the investment firm’s portfolio.
On June 15, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced the launch of T-Detect Lyme, the company’s second test to be made available from its growing T-Detect franchise. The test detects an immune response by leveraging the body’s unique T-cell response to disease-associated antigens.
Earlier this June, Piper Sandler analyst David Westenberg initiated coverage of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a Neutral rating and $7.50 price target. In a research note to investors, Westenberg states that the company’s lead analyzing the immune system, in the longer term, will have a “significant and sustainable” lead in diagnosing patients using the immune system. However, the analyst adds that the company’s best content are autoimmune and oncology launches, which are in 2024 or after.
Of the 912 elite funds tracked by Insider Monkey, 28 were long Adaptive Biotechnologies Corporation (NASDAQ:ADPT) at the end of March 2022, up from 22 in the fourth quarter of 2021. Andreas Halvorsen of Viking Global is the leading stakeholder of the company.
Similar to Block, Inc. (NYSE:SQ), Shopify Inc. (NYSE:SHOP), and Tesla, Inc. (NASDAQ:TSLA), Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is on the radar of institutional investors.
Here is what Aristotle Capital Management Small Cap Equity has to say about Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its Q1 2022 investor letter:
“Shares of Adaptive Biotechnologies were weak in the first quarter, despite the company reporting better-than-expected results and guiding in line with estimates in mid-February. High-valuation growth companies like Adaptive Biotechnologies continued to be pressured during the quarter, as investors weighed the risk of inflation and rising Treasury yields. On a positive note, clonoSEQ volumes continue to be strong and we believe 2022 is shaping up to be a catalyst rich year for the company.”
Click to continue reading and see 5 Small-Cap Growth Stocks in Cathie Wood’s Portfolio.
Suggested articles:
- 10 Best Dividend Stocks To Buy Now According to Noam Gottesman’s GLG Partners
- 10 Favorite Stocks of Billionaire Izzy Englander
- 10 Favorite Stocks of Dan Loeb’s Third Point
Disclosure: None. 10 Small-Cap Growth Stocks in Cathie Wood’s Portfolio. is originally published on Insider Monkey.
